Drug Discovery Solutions

Drug Discovery & Development

Jubilant Biosys and Jubilant Chemsys is a part of the Drug Discovery Solutions (DDS) arm of Jubilant Life Sciences and has global reach providing comprehensive drug discovery services – from target to clinical candidate in partnership with leading pharmaceutical and biotech companies worldwide.

With well enabled disease biology & pharmacology expertise in Oncology, Metabolic Disorders, CNS, Pain and Immuno-Inflammation Jubilant has emerged as one of the leading collaborator for biotechnology and pharmaceutical companies worldwide.

Jubilant has developed in-depth expertise in discovery informatics, computational chemistry / molecular modeling, medicinal chemistry, structural biology, in-vitro biology, disease biology & pharmacology, GLP toxicology, GMP and seamless integration of the above domains constitutes a powerful integrated drug discovery platform. The Drug Discovery Solutions arm has an augmented chemistry facility offering services in synthetic chemistry, library synthesis, analytical chemistry, process R&D and GMP.

Innovative and rigorous science, excellence in execution, and absolute integrity combined with flexible business models has enabled Jubilant to deliver differentiated outcomes in a relatively short period of time. The hallmark of Jubilant collaborative model is the creation of value to their partners.

 
Jubilant Advantage
  • Part of a large and stable organization with major investments in Life Sciences
  • A track-record of successful outcomes to large pharmaceuticals, mid-size biotechs & virtual companies on over 60 integrated programs (3 INDs and 5 Candidates)
  • Commitment to Innovation through investments in own platform and assets to partner with our clients
  • Flexible business models including risk share on integrated projects (38 discovery milestones achieved to date)
  • Many long term collaborations (FFS, FTE and integrated) due to consistent and quality delivery
  • IND enabling capabilities including GMP & GLP toxicology.
  • Single integrated site augmented by additional chemistry capacity.

Learn More about Drug Discovery Business :